Patents Assigned to Celgene Corporation
  • METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES
    Publication number: 20220160720
    Abstract: A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 26, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Peter H. SCHAFER, Shaojun TANG
  • Cereblon-based heterodimerizable chimeric antigen receptors
    Patent number: 11331380
    Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods thereof.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 17, 2022
    Assignee: CELGENE CORPORATION
    Inventor: Shuichan Xu
  • Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11325889
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, X, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: May 10, 2022
    Assignee: Celgene Corporation
    Inventors: Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
  • Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
    Patent number: 11312699
    Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 26, 2022
    Assignee: Celgene Corporation
    Inventors: Marie G. Beauchamps, Gregg Feigelson, Jianxin Han, Joshua Hansen, Mohit A. Kothare, Michael James Williams, Michael J. Zacuto, Weihong Zhang
  • Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11306101
    Abstract: Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure: wherein R1, R2, R3, R4 and n are as defined herein, compositions comprising an effective amount of a 1-oxo-isoindoline-5-carboxamide compound, and methods for treating or preventing disorders.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 19, 2022
    Assignee: Celgene Corporation
    Inventors: Frans Baculi, Katherine Northcote, Matthew D. Correa, Joshua Hansen, Laurie A. Lebrun, Chin-Chun Lu, Gang Lu, Mark A. Nagy, Sophie Peng, Sophie Perrin-Ninkovic
  • Antiproliferative compounds and methods of use thereof
    Patent number: 11241423
    Abstract: Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: February 8, 2022
    Assignee: Celgene Corporation
    Inventors: Brian E. Cathers, Joshua Hansen, Ehab M. Khalil, Antonia Lopez-Girona, Kyle MacBeth, Hon-Wah Man, George W. Muller, Michael Pourdehnad, Raj Raheja
  • Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
    Patent number: 11241439
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 8, 2022
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Methods of treatment of myeloproliferative neoplasm
    Patent number: 11229653
    Abstract: Provided are methods and compositions for treating myeloproliferative neoplasms patients carrying an IDH2 mutation and a JAK2 mutation.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 25, 2022
    Assignee: Celgene Corporation
    Inventors: Ross L. Levine, Anna Sophia McKenney
  • IMPROVED T CELL MANUFACTURING PROCESS
    Publication number: 20220017862
    Abstract: Provided herein are improved methods of manufacturing cells, including T cells and CAR T cells. Also provided herein are methods of manufacturing cells, such as T cells and CAR T cells, obtainable from blood using a method incorporating membrane filtration and Ammonium-Chloride-Potassium (ACK) buffer to isolate the cells from other blood components.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 20, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Thomas A. BRIEVA, David HSIUNG, Seth JONES, Shiv MISTRY, Nayyereh RAJAEI
  • METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
    Publication number: 20220003749
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: April 1, 2021
    Publication date: January 6, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Matthew William Burnell TROTTER, Patrick HAGNER, Courtney G. HAVENS, Rajesh CHOPRA, Anita GANDHI, Anke KLIPPEL, Maria Yinglin WANG, Mike BREIDER, Suzana Sturlini COUTO, Yan REN, Paul HOLLENBACH, Kyle MACBETH
  • Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
    Patent number: 11192847
    Abstract: Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: December 7, 2021
    Assignee: Celgene Corporation
    Inventors: Terrence Joseph Connolly, Hon-Wah Man
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210371522
    Abstract: CD47 antibodies that specifically inhibit the interaction between CD47 and the CD47-signal regulatory protein alpha (SIRP?) but not the interaction between CD47 and thrombospondin-1 (TSP-1), and methods of using these monoclonal antibodies as therapeutics are provided.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 2, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Pilgrim Jackson, Laure Escoubet, Kandasamy Hariharan, Michael Burgess, Kristen Hege, Heather Raymon, Piu Wong
  • Antiproliferative compounds and methods of use thereof
    Patent number: 11185543
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: November 30, 2021
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, James Carmichael, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
    Patent number: 11186556
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to salts of (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: November 30, 2021
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Daozhong Zou
  • Thienopyridine inhibitors of RIPK2
    Patent number: 11168093
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 9, 2021
    Assignee: Celgene Corporation
    Inventors: Kurt Armbrust, Fedor Romanov Michailidis, Karin Irmgard Worm, John Michael Ellis
  • USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210330788
    Abstract: The invention provides uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 28, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Kristen HEGE, Payal PATEL, Steven NOVICK, Lars STERNAS
  • Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11149007
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 19, 2021
    Assignee: Celgene Corporation
    Inventors: Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
  • METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTES
    Publication number: 20210309966
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 7, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Wei LIU
  • Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-peridine-2,6-dione
    Patent number: 11136306
    Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Celgene Corporation
    Inventors: Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
  • Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
    Patent number: RE48890
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorder associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: January 11, 2022
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis